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A B S T R A C T
Purpose
Individuals with advanced cancer experience substantial distress in response to disease burden and
impendingmortality. Managing Cancer And LivingMeaningfully (CALM) is a novel, brief, manualized
psychotherapeutic intervention intended to treat and prevent depression and end-of-life distress in
patients with advanced cancer. We conducted a randomized controlled trial to compare CALM with
usual care (UC) in this population.
Methods
Patients with advanced cancer were recruited from outpatient oncology clinics at a comprehensive
cancer center into an unblinded randomized controlled trial. Permuted block randomization stratified
by Patient Health Questionnaire-9 depression score allocated participants to CALM plus UC or to UC
alone. Assessments of depressive symptoms (primary outcome), death-related distress, and other
secondary outcomes were conducted at baseline, 3 months (primary end point), and 6 months (trial
end point). Analyses were by intention to treat. Analysis of covariance was used to test for outcome
differences between groups at follow-up, controlling for baseline. Mixed-model results are reported.
Results
Participants (n = 305) were recruited between February 3, 2012, and March 4, 2016, and randomly
assigned to CALM (n = 151) or UC (n = 154). CALM participants reported less-severe depressive
symptoms than UC participants at 3 months (D = 1.09; P = .04; Cohen’s d = 0.23; 95% CI, 0.04 to
2.13) and at 6 months (D = 1.29; P = .02; d = 0.29; 95% CI, 0.24 to 2.35). Significant findings for
greater end-of-life preparation at 6 months also favored CALM versus UC. No adverse effects were
identified.
Conclusion
Findings suggest that CALM is an effective intervention that provides a systematic approach to
alleviating depressive symptoms in patients with advanced cancer and addresses the predictable
challenges these patients face.
J Clin Oncol 36:2422-2432. © 2018 by American Society of Clinical Oncology. Licensed under the
Creative Commons Attribution 4.0 License: http://creativecommons.org/licenses/by/4.0/
INTRODUCTION
The diagnosis of advanced cancer may trigger
enormous distress and the challenge of living
meaningfully in the face of progressive disease.
Individuals in this situation face the burden of
physical suffering, the threat of dependency and
impending mortality, and the difficulty of making
treatment decisions that have life-and-death im-
plications while navigating a complex health care
system.1 Early palliative care for such individuals
has been shown to produce better outcomes,2-4 but
the psychological dimensions of such care are
much less systematized than those focused on
symptom control and advance care planning.
Ground-breaking research on supportive-
expressive therapy has demonstrated positive
effects on psychological outcomes in women with
metastatic breast cancer.5-7 More recently, three
systematic reviews of randomized controlled trials
(RCTs) confirmed that psychotherapy is effective
in treating depressive states in individuals with
advanced cancer, despite methodological limita-
tions in most studies.8-10 Both Dignity Therapy,11
a legacy-building intervention for those near the
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very end of life, andMeaning-Centered Psychotherapy,12,13 a group
or individual intervention that promotes a sense of meaning and
purpose in patients with advanced cancer, have been shown to be
effective in a variety of outcomes.13-15
We have developed a novel, brief, tailored supportive-
expressive psychotherapeutic intervention, referred to as Manag-
ing Cancer And Living Meaningfully (CALM) for patients with
advanced cancer and a prognosis of at least 1 year.16 On the basis of
relational, attachment, and existential theory, CALM provides
a therapeutic relationship and reflective space, with attention to the
following domains: symptom management and communication
with health care providers, changes in self and relations with close
others, spiritual well-being and the sense of meaning and purpose,
andmortality and future-oriented concerns.17 The CALMdomains
are addressed for each patient in a tailored, individualized manner
that allows for variation in the number of sessions and time spent
on each domain on the basis of the patient’s needs and health
status. CALM can be delivered by a wide range of trained psy-
chosocial oncology clinicians and cancer care providers.17
In pilot trials with patients with advanced cancer, we dem-
onstrated that CALM is feasible and found evidence of im-
provement in depression, death anxiety, spiritual well-being, and
attachment security.18,19 In qualitative interviews, participants
reported that CALM provides a “safe place” that helped them to
“be seen as a whole person by the medical system,” “grow as
a person,” and “be able to handle death in a peaceful way.”20 We
now report quantitative findings from an RCT of CALM. The
primary outcome was the severity of depressive symptoms, which
was selected because of evidence that depression is a final common
pathway of distress in this population.21 The primary end point of
3 months was chosen a priori to minimize the effects of attrition as
a result of disease progression; the secondary end point was
6 months. Secondary outcomes were selected on the basis of the
theoretical underpinnings of CALM and prior research21,22 and
included diagnosis of major depression, generalized anxiety, death-
related anxiety, spiritual well-being, quality of life at the end of life,
attachment security, couple communication, post-traumatic
growth, and demoralization.
Table 1. Comparison of CALM Intervention and UC
Variable CALM Intervention UC
Oncology clinics and distress screening Oncology clinic–based treatment and follow-up; routine
distress screening in clinics, with distress screening
results provided to oncology staff during clinic visit27
Oncology clinic–based treatment and follow-up; routine
distress screening in clinics, with distress screening
results provided to oncology staff during clinic visit27
Receipt of supportive care/psychosocial
oncology care
Yes (all participants) Oncology clinic staff may refer on the basis of clinical
judgment, patient request, or distress screening
Supportive care/psychosocial oncology
clinicians
Psychosocial clinicians trained in CALM* (eg, master’s
degree–level social workers and psychiatrists in the
present trial; may also be delivered by a wide range of
other trained cancer care providers eg, psychologists,
psychiatry residents, clinical nurse specialists, etc.);17
additional social work consultation for practical/
instrumental assistance, and/or psychiatry consultation
for monitoring or pharmacotherapy upon
recommendation of CALM therapist
Psychosocial clinicians (eg, master’s degree–level social
workers, psychiatrists, psychologists, psychiatry
residents)
Approximately 33% of patients with advanced cancer at
our center are referred for supportive care, 66% of
whom see social work for brief supportive interactions
and practical/instrumental assistance without
psychotherapy
Of the 33% seen by psychiatry or psychology, care
involves diagnostic consultation; treatment with
pharmacology, if needed; and/or brief, nonstandardized
psychotherapy that is integrative in nature and may
draw on other techniques, depending on need and
clinician training30
Clinician training* Clinicians attend a 2-day intensive CALM training
workshop, followed by competent completion of at
least two cases, as determined by the developers of
CALM (G.R. and S.H.) as well as weekly clinical case
supervision
Nonstandardized
Semistructured psychotherapy Three to six CALM sessions on average over 3 to 6
months (at least one session per month during first 3
months) individualized and tailored to patient’s needs in
both content and process
Less than 10% of patients with advanced cancer referred
receive any form of structured psychotherapy30
Modality Individual; primary caregiver (spouse or family member)
invited to participate in one or more CALM sessions as
deemed appropriate by patient and therapist
Nonstandardized
Manualized psychotherapy Yes (all participants), with attention to four broad domains:
symptommanagement and communication with health
care providers, changes in self and relations with close
others, spiritual well-being and the sense of meaning
and purpose, and mortality and future-oriented
concerns
None
Length of sessions Sessions on average 45 to 60 minutes Nonstandardized
Psychiatric monitoring and/or
pharmacotherapy
Yes, when clinically indicated; upon referral of treating
oncologist or as recommended by CALM therapist
Yes, when clinically indicated; upon referral of treating
oncologist
Palliative care Multidisciplinary palliative care28,29 upon referral of
treating oncologist or as recommended by CALM
therapist
Multidisciplinary palliative care28,29 upon referral of
treating oncologist
Abbreviations: CALM, Managing Cancer And Living Meaningfully; UC, usual care.
*CALM = UC + CALM. UC refers to usual cancer care delivered at the Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
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METHODS
Study Design
This unblinded, parallel assignment RCT had two trial conditions:
intervention plus usual care (UC) versus UC alone, with assessments at
baseline (t0), 3 months (t1; primary end point), and 6 months (t2; trial end
point). The trial protocol is provided in Lo et al.23 The site was the Princess
Margaret Cancer Centre (PM), which is part of the University Health
Network in Toronto, Ontario, Canada. This trial was approved by the
University Health Network Research Ethics Board (REB #09-0855-C) and
registered with ClinicalTrials.gov.
Participants
Inclusion criteria were $ 18 years of age; English fluency; no cognitive
impairment; and diagnosis of stage III or IV lung cancer, any-stage pancreatic
cancer (because of its aggressiveness), unresectable cholangiocarcinoma,
unresectable liver cancer, unresectable ampullary or peri-ampullary cancer or
other stage IV gastrointestinal (GI) cancer, stage III or IVovarian and fallopian
tube cancers or other stage IV gynecologic cancer, stage IV breast cancer,
genitourinary cancer, sarcoma, melanoma, or endocrine cancer. Diagnoses
were confirmed by chart review and consistent with an expected prognosis of
12 to 18 months on the basis of prior research in this population.22 Exclusion
criteria were major communication difficulties, cognitive impairment on the
basis of a Short Orientation-Memory-Concentration test score , 20,24
current psychiatric or psychological treatment in the Department of Sup-
portive Care at PM, unwillingness to accept random assignment or to commit
to the study, and prior participation in CALM therapy. Participants were
approved for trial enrollment by the principal investigators before random
assignment and provided written informed consent.
Randomization and Masking
Permuted block randomization was used to allocate participants,









































































Fig 1. CONSORT diagram. (*) Analyses
by intention to treat. CALM, Managing
Cancer And Living Meaningfully.
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(, 10 or$ 10)25 to ensure balance ofmoderate to severe depressive symptoms
between arms. The PM Biostatistics Department, which is independent of
the trial team, managed the randomization. Block sizes were variable and
unknown to the research team. Computer-generated randomization as-
signments were provided by the Biostatistics Department after the par-
ticipant’s baseline assessment.
Trial Conditions
On the basis of earlier trials,18,19 most intervention participants were
expected to receive three to six CALM psychotherapy sessions (each 45 to
60 minutes) over 3 to 6 months. The actual number of sessions each
participant received was based on clinical judgment and the patient’s ability
to participate. Therapists aimed to deliver at least three sessions within the
first 3 months of study enrollment. Noncompliance was defined as fewer
than three sessions over the course of the trial. The primary caregiver was
invited to one or more sessions when acceptable to the participant and
therapist. Therapists were five master’s degree–level social workers and
three psychiatrists. CALM training involved a 2-day workshop and sat-
isfactory completion of at least two cases under supervision with G.R. and
S.H., codevelopers of the intervention.16 Treatment integrity was main-
tained through weekly group supervision, which included a review of
session audiotapes and case discussion. After case presentations, G.R. and
S.H. used a treatment integrity rating scale (Appendix, online only)
adapted from Spiegel and Spira26 to assess the therapists, and these
evaluations were discussed to improve competencies.
Participants in the control group received UC alone (see Table 1 for
comparison with CALM), which included routine oncology treatment and
follow-up and clinic-based distress screening.27-29 UC did not preclude
referral for specialized psychosocial oncology services, but most patients
with metastatic cancer at PM do not receive psychotherapy as part of UC.30
Procedures
Patients with advanced cancer were identified through prescreening
of outpatient oncology clinic lists, and eligible patients were approached
for recruitment during clinic appointments. After informed consent,
research staff assessed cognitive functioning, readiness, and ability to
participate, administered baseline measures, conducted a diagnostic in-
terview for depression, and received enrollment approval from the study
principal investigators before contacting the PM Biostatistics Department
to receive randomization assignments. Participants were contacted at 3 and
6 months to complete follow-up assessments, which were conducted in
person at the hospital, by telephone, or by mail. Assessments were scanned
and scored by an independent data management company. The final data
set was exported to the trial team and to a biostatistician at PM (not part of
the trial team) for analysis and verification.
Outcome Measures
Primary outcome. The primary outcome was measured using the
PHQ-9,25 a reliable and valid measure of Diagnostic and Statistical Manual
of Mental Disorders, Fourth Edition (DSM-IV)31–concordant depression.
The PHQ-9 has been widely used in patients with advanced cancer.32
Secondary outcomes. The secondary outcomes were measured with
the following assessments:
Structured Clinical Interview for DSM-IV-TR Axis I Disorders (SCID),
Research Version,33 a semistructured interview for the diagnosis of
DSM-IV major depression31 (administered by research staff trained
and supervised by M.L.)
Generalized Anxiety Disorder-7 (GAD-7),34 a widely used and validated
measure to assess generalized anxiety symptoms
Death and Dying Distress Scale (DADDS),35 a valid measure in patients
with advanced cancer36 that rates distress about the dying process,
lost opportunities, and perceived burden on others
Functional Assessment of Chronic Illness Therapy-Spiritual Well-Being
Scale (FACIT-Sp-12),37 a measure of spiritual well-being validated
for use in cancer38 and widely used in palliative care research39
Quality of Life at the End of Life Cancer Scale (QUAL-EC),40 a short
form of the Quality of Life at the End of Life assessment41; we used
the following subscales relevant to psychosocial functioning: prep-
aration for the end of life (ie, extent to which the family is prepared
and financial plans made), relationship with health care providers
(ie, extent to which patients feel informed and are able to participate
in decisions about their care), and sense of life completion (ie, ability
to share important things and to feel connected to others)
16-Item Experiences in Close Relationships Scale validated for use in
advanced cancer (ECR-M16),42 a modified and brief version of the
Experiences in Close Relationships assessment43 that measures at-
tachment insecurity (ie, reflects difficulty in trusting and relying on
close others in times of need)44
Couple Communication Scale (CCS)45 for participants in long-term
relationships, a part of the validated PREPARE/ENRICH Inventory45
that assesses the quality of communication in the dyad
Posttraumatic Growth Inventory (PTGI),46 a valid measure previously
used in cancer to assess positive psychological changes after trauma47
Demoralization Scale (DS),48 a validated measure of the experience of
disheartenment and helplessness
Additional data collected were demographics, medical history,
Karnofsky performance status,49 and the presence and severity of 28
Table 2. Baseline Sample Characteristics
Characteristic UC, % (No.) CALM,%(No.) P
No. of participants (n = 305) 154 151
Mean age, years (SD) 59.10 (11.48) 59.05 (10.55) .97
Female 60 (92) 60 (90) .98
White 84 (129) 84 (127) .94
Married/common law 71 (109) 72 (108) .96
Postsecondary education 84 (129) 82 (123) .68
Mean duration of illness,
years (SD)*
1.68 (2.12) 1.49 (1.74) .39
Cancer type .93
Breast 8 (13) 9 (13)
Lung 12 (18) 16 (24)
Sarcoma 6 (10) 5 (7)
Melanoma 2 (3) 2 (3)
Endocrine 3 (5) 3 (5)
GI 26 (40) 26 (39)
Gynecologic 27 (41) 22 (33)
Genitourinary 16 (24) 18 (27)
MSAS†
Mean symptom count (SD) 12.88 (4.33) 12.57 (5.08) .57
Mean symptom severity‡ (SD) 1.77 (0.41) 1.75 (0.43) .68
Mean Karnofsky performance score§
(SD)
79.90 (8.83) 80.00 (10.71) .93
Antidepressant use 18 (28) 10 (15) .04k
PHQ-9 $ 8 points¶ 44 (68) 43 (65) .85
NOTE. CALM = UC + CALM.
Abbreviations: CALM, Managing Cancer And Living Meaningfully; MSAS,
Memorial Symptom Assessment Scale; PHQ-9, Patient Health Questionnaire-9;
SD, standard deviation; UC, usual care.
*Duration of illness refers to the time from advanced or metastatic cancer
diagnosis (meeting CALM eligibility) to trial enrollment (randomization date);
sample range, 0 to 11.75 years; n = 153 in the UC group.
†Symptom count range, 0 to 28; severity range, 1 to 4; higher values are worse.
‡n = 150 in CALM group.
§Scale ratings range from 100 (normal, no complaints) downward in decre-
ments of 10 to 0 (death). The average Karnofsky performance score for the
sample (80) reflects that participants on average were able to carry on normal
activity with effort, some signs or symptoms of disease (sample range, 100
[normal, no complaints; n = 12] to 50 [requires considerable assistance and
frequent medical care; n = 1]).49
kP , .05.
¶PHQ-9 $ 8 points reflects depressive symptoms of at least threshold
severity.54
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common cancer symptoms assessed using a shortened version of the
Memorial Symptom Assessment Scale.50
Statistical Analysis
A sample size recalculation was conducted in February 2014 using
actual attrition and compliance rates rather than pretrial estimates and
without examination of treatment effects. A total baseline sample of at least
242 participants would power this trial to detect a small to medium effect
size (Cohen’s d)51 of 0.405.19 With available resources, we chose to extend
recruitment to reach at least 100 trial completionists per arm, which was
achieved after consenting 413 participants, 305 of whom were randomly
assigned.
Analyses were by intention to treat. Analysis of covariance was used to
examine outcome differences between trial arms at follow-up, controlling
for baseline scores. The main analyses were conducted on available par-
ticipants, P values correspond to two-tailed tests and a was set at .05. As
a sensitivity analysis, we used multiple imputation with the Markov
model52 to address the issue of missing data (Appendix Table A1, online
only) and report P values that tested the aggregate results of 20 impu-
tations, which achieved 0.99 relative efficiency on the primary outcome
and stabilized estimates. The imputation model included the relevant t0,
t1, and t2 outcome assessments and randomization. We used the false
discovery rate (FDR)53 method to control for multiple comparisons on the
secondary outcomes and report FDR-adjusted P values. The FDR was
applied separately to the family of tests at 3 and 6 months. The familywise
FDR was set to .05. Trial analyses were independently verified by a member
of the PMBiostatistics Department. Analyses for this article were generated
using SAS/STAT 9.3 statistical software (SAS Institute, Cary, NC).
To clarify the clinical meaning of effects on the primary outcome,
we conducted post hoc analyses with regard to the emergence and
remission rates of depressive symptoms of at least threshold severity
(indicated by PHQ-9$ 8 points),54 and the proportion of patients with
a PHQ-9 reduction greater than the minimal clinically important
difference (MCID) of 5 points55 in participants with depressive
symptoms of at least threshold severity. Prespecified subanalyses were
conducted for groups with low, moderate, or high death anxiety at
baseline (using DADDS cutoffs of , 25 and $ 47 points to distinguish
approximately the upper and lower thirds of the sample) because these
groups may differ in the processing of death-related distress.56 Finally,
mixed models were conducted as supplementary analyses to examine
treatment effects across outcomes, regressing each outcome on trial arm
(UC, CALM), time (t0, t1, t2), and their interaction, with intercepts set as
random effects.
RESULTS
Four hundred and thirteen patients consented to participate be-
tween February 3, 2012, and March 4, 2016, 305 of whom were
randomly assigned to CALM (n = 151) and UC (n = 154; Fig 1).
Contamination (defined as two or more psychotherapy sessions
with a CALM-trained PM clinician) was 2% in control partici-
pants. Participation in at least three sessions was considered
a minimal intervention. On the basis of this criterion, compliance
with the intervention was 54.3% in the CALM group at 3 months
(mean, 3 sessions; range, 0 to 7 sessions) and 77.5% by 6 months
(mean, 4 sessions; range, 0 to 10 sessions). Of those who received
three or more sessions over 6 months, 64.2% received three to six
sessions and 13.3% received seven to 10 sessions; of the remaining
CALM participants, 17.2% received one or two sessions and 5.3%
received no sessions. The majority of sessions were delivered in
outpatient clinics; a small number were delivered to very ill
Table 3. Primary Outcome and Its Clinical Effect
Primary Outcome and Time Point UC CALM D
OR
(CALM v UC) 95% CI d P Multiple Imputation P
PHQ-9
t0
Mean (SD) 7.41 (4.75) 7.45 (4.96) — — — — — —
No. of participants 154 151
t1
Mean (SD) 7.01 (4.82) 5.97 (4.83) 1.09 — 0.04 to 2.13 0.23 .04* .04*
No. of participants 128 119
t2
Mean (SD) 6.64 (4.97) 5.35 (3.99) 1.29 — 0.24 to 2.35 0.29 .02* .007*
No. of participants 118 107
Clinical impact, % (frequency/No.)
PHQ-9 reduction $ MCID (5 points)†
t1 33 (19 of 58) 52 (27 of 52) — 2.22 1.02 to 4.80 .04*
t2 35 (19 of 54) 64 (28 of 44) — 3.22 1.41 to 7.39 .005*
Remission†
t1 38 (22 of 58) 56 (29 of 52) — 2.06 0.96 to 4.42 .06
t2 37 (20 of 54) 66 (29 of 44) — 3.29 1.43 to 7.56 .005*
Emergence‡
t1 30 (21 of 70) 13 (9 of 67) — 0.36 0.15 to 0.86 .02*
t2 19 (12 of 64) 11 (7 of 63) — 0.54 0.20 to 1.48 .23
NOTE. D is the regression-estimated mean difference between groups controlled for baseline. Cohen’s d (effect size) is the standardized mean difference. Effect sizes
of 0.20 to 0.50 are considered small to medium.51 The analyses of clinical effect, including CIs for ORs, involved simple Pearson x2 tests without continuity correction.
CALM = UC + CALM.
Abbreviations: CALM, Managing Cancer And Living Meaningfully; MCID, minimal clinically important difference; OR, odds ratio; PHQ-9, Patient Health Questionnaire-9
(score range, 0 to 27; higher scores reflect greater depressive symptom severity); t0, baseline assessment; t1, 3-month assessment (primary end point); t2, 6-month
assessment (trial end point); UC, usual care.
*P , .05.
†In participants with depressive symptoms of at least threshold severity (PHQ-9 $ 8 points) at baseline.
‡In participants with depressive symptoms less than threshold severity (PHQ-9 , 8 points) at baseline.
2426 © 2018 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
Rodin et al
Downloaded from ascopubs.org by James Cook University on August 30, 2021 from 137.219.201.141
Copyright © 2021 American Society of Clinical Oncology. All rights reserved. 
Table 4. Secondary Outcomes
Secondary Outcome UC CALM D 95% CI d P
SCID: major depression*
t0
% (No.) 8 (12) 4 (6) — — — —
No. of participants 154 149
t1
% (No.) 6 (8) 2 (2) — — — —
No. of participants 125 117
t2
% (No.) 3 (3) 1 (1) — — — —
No. of participants 114 106
GAD-7: generalized anxiety
t0
Mean (SD) 5.84 (4.31) 5.31 (3.63) — — — —
No. of participants 153 151
t1
Mean (SD) 5.56 (4.66) 4.47 (3.75) 0.64 20.32 to 1.59 0.15 .19
No. of participants 121 113
t2
Mean (SD) 5.48 (4.68) 4.37 (4.10) 0.79 20.26 to 1.85 0.18 .14
No. of participants 113 103
DADDS: death anxiety (total sample)
t0
Mean (SD) 35.64 (16.88) 33.77 (16.89) — — — —
No. of participants 154 151
t1
Mean (SD) 30.66 (18.00) 27.39 (16.85) 1.60 21.91 to 5.11 0.09 .37
No. of participants 123 114
t2
Mean (SD) 30.40 (17.61) 27.80 (18.16) 1.83 21.99 to 5.64 0.10 .35
No. of participants 115 102
FACIT-Sp-12: spiritual well-being
t0
Mean (SD) 29.60 (8.76) 28.69 (8.65) — — — —
No. of participants 154 151
t1
Mean (SD) 31.19 (9.17) 30.77 (8.27) 20.52 22.05 to 1.01 0.06 .50
No. of participants 121 113
t2
Mean (SD) 30.50 (9.62) 31.09 (8.29) 21.43 23.17 to 0.30 0.16 .11
No. of participants 116 103
QUAL-EC: preparation for end of life
t0
Mean (SD) 11.62 (3.78) 12.07 (3.73) — — — —
No. of participants 154 151
t1
Mean (SD) 11.72 (3.84) 13.01 (3.75) 20.99 21.68 to 20.29 0.26 .007†
No. of participants 121 113
t2
Mean (SD) 12.17 (3.97) 13.49 (3.50) 21.20 21.92 to 20.48 0.32 .001†
No. of participants 115 103
QUAL-EC: relationship with health care provider
t0
Mean (SD) 17.23 (3.70) 17.28 (3.94) — — — —
No. of participants 154 151
t1
Mean (SD) 18.15 (3.86) 17.17 (4.04) 0.82 0.04 to 1.61 0.21 .04†
No. of participants 121 113
t2
Mean (SD) 18.05 (3.76) 17.71 (3.84) 0.12 20.68 to 0.91 0.03 .73
No. of participants 115 102
QUAL-EC: life completion
t0
Mean (SD) 18.23 (3.79) 18.53 (4.00) — — — —
No. of participants 154 151
t1
Mean (SD) 18.62 (3.72) 18.08 (4.04) 0.55 20.26 to 1.37 0.14 .18
No. of participants 121 113
(continued on following page)
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participants by telephone or in the inpatient palliative care unit.
Mean treatment integrity ratings indicated that most therapeutic
competencies were satisfactory to excellent, with themost room for
improvement in the offering of interpretations (Appendix Fig A1,
online only). The overall attrition rate at 6 months (trial end point)
was 25.5% (15.4% died, 6.2% were lost to follow-up, and 3.9%
withdrew), with 70.9% of the CALM group and 77.9% of the UC
group completing the trial. Final trial follow-ups were completed
by September 2016. Mortality 1 year after trial completion was
67.5% (206 of 305 participants [109 CALM participants, 97 UC
participants]).
No trial group differences existed at baseline (Table 2), except
for antidepressant use (18% UC v 10% CALM). Preliminary
analyses that controlled for this factor found that it was non-
significant and did not affect the pattern and magnitude of
findings; therefore, we report group differences without
Table 4. Secondary Outcomes (continued)
Secondary Outcome UC CALM D 95% CI d P
t2
Mean (SD) 18.72 (3.83) 18.47 (3.88) 0.17 20.62 to 0.96 0.04 .67
No. of participants 115 103
ECR-M16: attachment insecurity
t0
Mean (SD) 44.50 (15.03) 42.60 (14.64) — — — —
No. of participants 154 151
t1
Mean (SD) 43.64 (15.73) 41.13 (13.91) 1.24 21.63 to 4.12 0.08 .39
No. of participants 121 113
t2
Mean (SD) 44.14 (16.19) 40.66 (12.71) 2.83 20.15 to 5.80 0.19 .06
No. of participants 116 101
CCS: couple communication
t0
Mean (SD) 36.48 (8.20) 39.15 (6.99) — — — —
No. of participants 115 120
t1
Mean (SD) 38.38 (7.63) 38.32 (7.61) 1.73 0.10 to 3.37 0.23 .04†
No. of participants 91 92
t2
Mean (SD) 38.31 (7.79) 38.44 (7.69) 1.37 20.30 to 3.04 0.18 .11
No. of participants 81 84
PTGI: post-traumatic growth
t0
Mean (SD) 54.93 (21.28) 49.16 (21.32) — — — —
No. of participants 154 151
t1
Mean (SD) 56.72 (22.29) 50.56 (23.76) 0.27 23.88 to 4.43 0.01 .90
No. of participants 120 112
t2
Mean (SD) 54.18 (23.64) 51.68 (21.72) 21.35 26.13 to 3.43 0.06 .58
No. of participants 115 103
DS: demoralization
t0
Mean (SD) 28.41 (14.24) 27.03 (13.52) — — — —
No. of participants 154 151
t1
Mean (SD) 25.46 (14.10) 24.97 (14.54) 20.37 23.12 to 2.38 0.03 .80
No. of participants 119 113
t2
Mean (SD) 25.76 (14.47) 23.15 (15.04) 2.34 20.51 to 5.19 0.16 .11
No. of participants 116 103
NOTE. CALM refers to UC + CALM. D is the regression-estimated mean difference between groups controlled for baseline, when relevant. Cohen’s d (effect size) is the
standardized mean difference. Effect sizes of 0.20 to 0.50 are considered small to medium.51Abbreviations: CALM, Managing Cancer And Living Meaningfully; CCS,
Couple Communication Scale (score range, 10 to 50; higher scores reflect better communication); DADDS, Death and Dying Distress Scale (score range, 0 to 75; higher
scores reflect greater death anxiety); DS, Demoralization Scale (score range, 0 to 96; higher scores reflect a greater sense of demoralization); ECR-M16, modified
Experiences in Close Relationships Scale (score range, 8 to 56; higher scores reflect greater attachment insecurity [ie, greater attachment avoidance and greater
attachment anxiety]); FACIT-Sp-12, Functional Assessment of Chronic Illness Therapy-Spiritual Well-Being Scale (score range, 0 to 21; higher scores reflect greater
spiritual well-being); GAD-7, Generalized Anxiety Disorder-7 (score range, 0 to 21; higher scores reflect greater generalized anxiety); QUAL-EC, Quality of Life at the End
of Life Cancer Scale (higher scores reflect greater preparation for end of life score range, 4 to 20; greater communication with health care providers score range, 5 to 25;
greater sense of life completion score range, 5 to 25); PTGI, Posttraumatic Growth Inventory (score range, 0 to 105; higher scores reflect greater post-traumatic growth);
SCID, Structured Clinical Interview for DSM-IV-TR (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision) Disorders (major depression
assessed by clinical interview on the basis of DSM-IV diagnostic criteria27); SD, standard deviation; t0, baseline assessment; t1, 3-month assessment (primary end point);
t2, 6-month assessment (trial end point); UC, usual care.
*Insufficient number of participants for analysis.
†P , .05.
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covariables. Of note, as the study progressed, the group difference
on antidepressant use was nonsignificant at 3 months (UC, 19.5%
[25 of 128]; CALM, 11.8% [14 of 119]; P = .09) and at 6 months
(UC, 17.1% [20 of 117]; CALM, 12.3% [13 of 106]; P = .31).
Table 3 lists primary outcome results. The CALM group
reported less-severe depressive symptoms than the UC group at the
primary end point of 3 months (d = 0.23; P = .04). This effect
appeared to be greater at 6 months (d = 0.29; P = .02). Analysis of
multiple imputations yielded the same patterns of effect.
To clarify clinical meaning, we conducted post hoc analyses
of remission and emergence rates of at least threshold depression
(PHQ-9 $ 8 points54; Table 3). CALM participants were more
likely to show remission of symptoms of at least threshold se-
verity at 6 months (odds ratio [OR], 3.29; P = .005) and were less
likely to develop depressive symptoms of at least threshold se-
verity at 3 months (OR, 0.36; P = .02). For participants with
depressive symptoms of at least threshold severity, CALM was
more likely to provide a clinically important PHQ-9 reduction
(minimal clinically important difference [MCID], 5 points)55
at 3 months (OR, 2.22; P = .04) and at 6 months (OR, 3.22;
P = .005).
Table 4 lists the secondary outcomes, and Table 5 lists the
FDR-adjusted P values and multiple imputation results. With
a focus on the most robust findings, a significant treatment effect
was found for preparation for end of life at both 3 and 6 months
in CALM participants compared with UC that was sustained after
multiple imputation, although the 3-month effect was rendered
nonsignificant after controlling for multiple comparisons. No
adverse effects were reported. Some outcomes (couple com-
munication and relationship with health care providers) were
better in the UC group at 3 months, although these effects were
rendered nonsignificant after multiple imputations and con-
trolling for multiple comparisons and were not sustained at
6 months.
The sample was stratified into low, moderate, and high
groups for death anxiety subanalyses. Within each stratum, we
tested for treatment effects on secondary outcomes associated
with death anxiety.35,36,56 CALM participants with moderate
death anxiety had significantly lower DADDS scores at both 3 and
6 months than UC participants (d = 0.46 and 0.68, respectively).
At 6 months, CALM participants also reported less generalized
anxiety and demoralization and greater spiritual well-being and
attachment security than UC participants in the same DADDS
range (d range, 0.43 to 0.50; Table 6). No other effects were found
in the lowest and highest death anxiety strata (Appendix Table A2,
online only).
Results from the mixed-model supplementary analyses sup-
ported the main analyses. Appendix Table A3 (online only) lists
trial arm 3 time interactions for all outcomes. The CALM group
was expected to show less distress and greater benefit over time
relative to the UC group. Significant effects on depressive symp-
toms, preparation for end of life, and CCS were found. Appendix
Table A4 (online only) lists the mixed-model estimated means that
explain the significant trial arm 3 time interactions. The CALM
group showed a pattern of steeper decline in depressive symptoms
and greater end-of-life preparation over time than the UC group.
With regard to the CCS, the two groups seemed to differ at baseline
and came to parity over time.
DISCUSSION
In this RCTof a tailored supportive-expressive therapy for patients
with advanced disease and expected prognosis of at least
12 months,22 we found significant improvement in the intervention
group in the severity of depressive symptoms at 3 months compared
with UC, with an apparently greater effect at 6 months compared
with UC. CALM was effective in achieving clinically important
reductions in depressive symptom severity at 3 and 6 months in
participants with at least threshold symptoms and in the rate of
remission of threshold symptoms by trial end. We also found
a significant treatment effect that favored CALM at the 6-month
end point for greater end-of-life preparation compared with UC.
Among participants who were not depressed at baseline, those
who received CALM were less likely to report threshold symptoms
at the primary end point, which suggests that CALM may help to
prevent the onset of depressive symptoms that may otherwise grow
over time in individuals with advanced disease.55 Although some
have suggested the restriction of depression intervention trials in
cancer to participants with major depression to avoid floor ef-
fects,57 this approach may obscure effects on prevention of de-
pressive symptoms in patients without depression.
Evidence with regard to the mechanisms by which CALM
exerts its effects will be reported in a separate publication. These
mechanisms may include the opportunity for participants to
discuss communication with health care providers, to address the
Table 5. Sensitivity Analyses for Secondary Outcomes






QUAL-EC: preparation for end of life .007* .07 .009*
CCS .04* .13 .06
QUAL-EC: relationship with health
care provider
.04* .13 .07
QUAL-EC: life completion .18 .38 .26
GAD-7 .19 .38 .11
DADDS .37 .56 .45
ECR-M16 .39 .56 .38
FACIT-Sp-12 .50 .63 .44
DS: demoralization .79 .88 .90




.001* .01* , .001*
ECR-M16 .06 .22 .06
CCS .11 .22 .13
FACIT-Sp-12 .11 .22 .15
DS: demoralization .11 .22 .09
GAD-7 .14 .23 .12
DADDS .35 .50 .48
PTGI .58 .73 .71




Abbreviations: CCS, Couple Communication Scale; DADDS, Death and Dying
Distress Scale; DS, Demoralization Scale; ECR-M16, modified Experiences in
Close Relationships Scale; FACIT-Sp-12, Functional Assessment of Chronic
Illness Therapy-Spiritual Well-Being Scale; FDR, false discovery rate; GAD-7,
Generalized Anxiety Disorder-7; PTGI, Posttraumatic Growth Inventory; QUAL-
EC, Quality of Life at the End of Life Cancer Scale; t1, 3-month assessment
(primary end point); t2, 6-month assessment (trial end point).
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effect of their disease on their self-concept and family relationships,
to find or reclaim a sense of meaning and purpose in life, to express
and manage fears and wishes related to the end of life, and to begin
preparations for end of life. CALM addresses these concerns to alter
what we have termed a final common pathway of distress that leads
to depression in this population.21 Such a targeted approach is
Table 6. Subanalyses of Participants With Moderate Death Anxiety at Baseline
Secondary Outcome by Time UC CALM D 95% CI d P
DADDS: death anxiety
t0
Mean (SD) 33.60 (6.25) 35.85 (6.76) — — — —
No. of participants 68 68
t1
Mean (SD) 31.53 (13.24) 27.19 (12.15) 5.82 0.92 to 10.73 0.46 .02*
No. of participants 55 47
t2
Mean (SD) 31.59 (14.96) 23.51 (15.10) 10.06 4.17 to 15.95 0.68 .001*
No. of participants 49 41
FACIT-Sp-12: spiritual well-being
t0
Mean (SD) 30.43 (7.99) 28.02 (7.87) — — — —
No. of participants 68 68
t1
Mean (SD) 30.86 (7.98) 29.79 (7.61) 21.48 23.78 to 0.83 0.19 .21
No. of participants 55 47
t2
Mean (SD) 29.59 (7.86) 31.51 (7.73) 23.59 26.21 to 20.96 0.47 .008*
No. of participants 49 41
ECR-M16: attachment insecurity
t0
Mean (SD) 40.60 (14.01) 43.15 (12.77) — — — —
No. of participants 68 68
t1
Mean (SD) 39.63 (13.61) 41.60 (13.71) 1.51 22.54 to 5.57 0.11 .46
No. of participants 55 47
t2
Mean (SD) 43.50 (15.50) 41.48 (12.25) 6.09 1.43 to 10.75 0.44 .01*
No. of participants 49 40
GAD-7: generalized anxiety
t0
Mean (SD) 5.15 (3.46) 5.16 (2.83) — — — —
No. of participants 67 68
t1
Mean (SD) 5.33 (4.58) 4.26 (2.96) 0.83 20.54 to 2.21 0.22 .23
No. of participants 55 47
t2
Mean (SD) 5.51 (4.57) 3.78 (3.24) 1.70 0.18 to 3.21 0.43 .03*
No. of participants 47 41
DS: demoralization
t0
Mean (SD) 26.06 (9.82) 28.16 (9.33) — — — —
No. of participants 68 68
t1
Mean (SD) 23.98 (11.15) 24.96 (12.10) 1.16 22.73 to 5.05 0.10 .56
No. of participants 53 47
t2
Mean (SD) 25.96 (13.41) 22.05 (11.37) 6.24 1.54 to 10.93 0.50 .01*
No. of participants 49 41
NOTE.We hypothesized that the effects of intervention would vary dependent on the levels of death anxiety (low, moderate, or high) that patients were experiencing.56
We expected that the moderate group would exhibit the most benefit because participants would have sufficient awareness of the threat of mortality and resiliency to
address this issue and prepare for end of life. Those in the high and low groups were expected to show less or no benefit. Those in the high group were expected to have
more intractable physical and psychosocial concerns that caused their scores to be elevated into this range and that their death anxiety may be less amenable to change.
Those in the low group might be subject to floor effects or may lack sufficient awareness of the threat of mortality to be able to show benefit on distress outcomes over
time. D is the regression-estimated mean difference between groups controlled for baseline. Cohen’s d (effect size) is the standardized mean difference. Effect sizes of
0.20 to 0.50 are considered small to medium.51
Abbreviations: CALM,Managing Cancer And LivingMeaningfully; DADDS, Death and Dying Distress Scale (higher scores reflect greater death anxiety; moderate death
anxiety was defined as a score of $ 25 to , 47 points); DS, Demoralization Scale (higher scores reflect a greater sense of demoralization); ECR-M16, modified
Experiences in Close Relationships Scale (higher scores reflect greater attachment insecurity [ie, greater attachment avoidance and greater attachment anxiety]); FACIT-
Sp-12, Functional Assessment of Chronic Illness Therapy-Spiritual Well-Being Scale (higher scores reflect greater spiritual well-being); GAD-7, Generalized Anxiety
Disorder-7 (higher scores reflect higher generalized anxiety); SD, standard deviation; t0, baseline assessment; t1, 3-month assessment (primary end point); t2, 6-month
assessment (trial end point); UC, usual care.
*P , .05.
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consistent with the view that positive outcomes and sustained
improvement are most likely to occur when the treatment of
depression is directed at etiologic and pathogenic factors58 and at
subsystems of variables that interact in specific contexts.59
The study findings suggest that participants with moderate
levels of distress about dying and death benefitedmost fromCALM
therapy in terms of reduction of such distress and improvement on
the secondary outcomes of generalized anxiety, demoralization,
spiritual well-being, and attachment security. Those with the
lowest levels of death-related distress may be managing death-
related concerns effectively and/or may be nonreflective about
them; those with the highest levels may feel too overwhelmed to be
able or willing to participate in conversations about such issues.56
Additional research is needed to clarify which patients might
benefit most from CALM and to identify the optimal point in the
disease trajectory for CALM to be initiated.
Limitations of this study include that it was conducted at
a single site in a large Canadian city with primarily English-speaking,
white, well-educated participants, who may not be representative of
other settings. The recruitment rate from oncology clinics is
comparable to that with other psychotherapeutic interventions in
similar settings,60 although this may limit the generalizability of the
findings. Strengths include the relatively high intervention com-
pliance and completion rates. More than 77% of participants
randomly assigned to CALM were compliant with the intervention,
and only 10% of those withdrew or were lost to follow-up over
6 months, mainly as a result of disease progression.
In summary, the findings of this RCT suggest that CALM
therapy may help to relieve and prevent depressive symptoms in
individuals with advanced disease and help patients to address
preparations for the end of life. Additional research is needed to
explore the optimal timing of CALM, the specific mechanisms of
therapeutic action, the most appropriate and meaningful outcome
measures, and feasibility and effectiveness of CALM in diverse
cultural and clinical settings.
AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS
OF INTEREST
Disclosures provided by the authors are available with this article at
jco.org.
AUTHOR CONTRIBUTIONS
Conception and design: Gary Rodin, Christopher Lo, Anne Rydall,
Carmine Malfitano, Aubrey Chiu, Tania Panday, Rinat Nissim, Madeline
Li, Camilla Zimmermann, Sarah Hales
Collection and assembly of data: Anne Rydall, Joanna Shnall, Carmine
Malfitano, Aubrey Chiu, Tania Panday, Sarah Watt, Ekaterina An
Data analysis and interpretation: Gary Rodin, Christopher Lo, Madeline
Li, Sarah Hales
Manuscript writing: All authors
Final approval of manuscript: All authors
Accountable for all aspects of the work: All authors
REFERENCES
1. Rodin G: Individual psychotherapy for the
patient with advanced disease, in Chochinov H,
Breitbart W (eds): Handbook of Psychiatry in Pallia-
tive Medicine. London, UK, Oxford University Press,
2009, pp 443-453
2. Temel JS, Greer JA, Muzikansky A, et al: Early
palliative care for patients with metastatic non-small-
cell lung cancer. N Engl J Med 363:733-742, 2010
3. Temel JS, Greer JA, El-Jawahri A, et al: Effects
of early integrated palliative care in patients with lung
and GI cancer: A randomized clinical trial. J Clin Oncol
35:834-841, 2017
4. Zimmermann C, Swami N, Krzyzanowska M,
et al: Early palliative care for patients with advanced
cancer: A cluster-randomised controlled trial. Lancet
383:1721-1730, 2014
5. Spiegel D, Bloom JR, Yalom I: Group support
for patients with metastatic cancer. A randomized
outcome study. ArchGen Psychiatry 38:527-533, 1981
6. Spiegel D, Classen C. Group Therapy for
Cancer Patients: A Research-Based Handbook of
Psychosocial Care. New York, NY, Basic Books, 2000
7. Classen C, Butler LD, Koopman C, et al:
Supportive-expressive group therapy and distress in
patients withmetastatic breast cancer: A randomized
clinical intervention trial. Arch Gen Psychiatry 58:
494-501, 2001
8. Akechi T, Okuyama T, Onishi J, et al: Psy-
chotherapy for depression among incurable cancer
patients. Cochrane Database Syst Rev (2):
CD005537, 2008
9. Li M, Kennedy EB, Byrne N, et al: Systematic
review and meta-analysis of collaborative care
interventions for depression in patients with
cancer. Psychooncology 26:573-587, 2017
10. Okuyama T, Akechi T, Mackenzie L, et al:
Psychotherapy for depression among advanced, in-
curable cancer patients: A systematic review and
meta-analysis. Cancer Treat Rev 56:16-27, 2017
11. Chochinov HM, Hack T, Hassard T, et al:
Dignity therapy: A novel psychotherapeutic in-
tervention for patients near the end of life. J Clin
Oncol 23:5520-5525, 2005
12. Breitbart W, Gibson C, Poppito SR, et al:
Psychotherapeutic interventions at the end of life: A
focus on meaning and spirituality. Can J Psychiatry
49:366-372, 2004
13. Breitbart W, Rosenfeld B, Pessin H, et al:
Meaning-centered group psychotherapy: An effec-
tive intervention for improving psychological well-
being in patients with advanced cancer. J Clin
Oncol 33:749-754, 2015
14. BreitbartW, Poppito S, Rosenfeld B, et al: Pilot
randomized controlled trial of individual meaning-
centered psychotherapy for patients with advanced
cancer. J Clin Oncol 30:1304-1309, 2012
15. Chochinov HM, Kristjanson LJ, Breitbart W,
et al: Effect of dignity therapy on distress and end-of-
life experience in terminally ill patients: A randomised
controlled trial. Lancet Oncol 12:753-762, 2011
16. Hales S, Lo C, Rodin G. Managing Cancer And
Living Meaningfully (CALM) Treatment Manual: An
Individual Psychotherapy for Patients with Advanced
Cancer. Toronto, Ontario, Canada, Princess Margaret
Cancer Centre, University Health Network, 2015
17. Hales S, Lo C, Rodin G: Managing Cancer And
Living Meaningfully (CALM) therapy, in Holland JC,
Breitbart WS, Butow PN, et al (eds), Psycho-Oncology.
New York, NY, Oxford University Press,. 2015, pp 487-491
18. Lo C, Hales S, Jung J, et al: Managing Cancer
And Living Meaningfully (CALM): Phase 2 trial of
a brief individual psychotherapy for patients with
advanced cancer. Palliat Med 28:234-242, 2014
19. Lo C, Hales S, Chiu A, et al: Managing Cancer
And Living Meaningfully (CALM): Randomised fea-
sibility trial in patients with advanced cancer. BMJ
Support Palliat Care 10.1136/bmjspcare-2015-
000866 [epub ahead of print on January 19, 2016]
20. Nissim R, Freeman E, Lo C, et al: Managing
Cancer And Living Meaningfully (CALM): A qualita-
tive study of a brief individual psychotherapy for in-
dividuals with advanced cancer. Palliat Med 26:
713-721, 2012
21. Rodin G, Lo C, Mikulincer M, et al: Pathways
to distress: The multiple determinants of depression,
hopelessness, and the desire for hastened death in
metastatic cancer patients. Soc Sci Med 68:562-569,
2009
22. Lo C, Zimmermann C, Rydall A, et al: Longi-
tudinal study of depressive symptoms in patients
with metastatic gastrointestinal and lung cancer.
J Clin Oncol 28:3084-3089, 2010
23. Lo C, Hales S, Rydall A, et al: Managing Cancer
And Living Meaningfully: Study protocol for a ran-
domized controlled trial. Trials 16:391, 2015
24. Katzman R, Brown T, Fuld P, et al: Validation of
a short Orientation-Memory-Concentration Test of
cognitive impairment. Am J Psychiatry 140:734-739,
1983
25. Kroenke K, Spitzer RL, Williams JBW: The
PHQ-9: Validity of a brief depression severity mea-
sure. J Gen Intern Med 16:606-613, 2001
26. Spiegel D, Spira P. Supportive-Expressive
Group Therapy: A Treatment Manual of Psychoso-
cial Intervention for Women With Recurrent Breast
jco.org © 2018 by American Society of Clinical Oncology 2431
Psychological Intervention for Patients With Advanced Cancer
Downloaded from ascopubs.org by James Cook University on August 30, 2021 from 137.219.201.141
Copyright © 2021 American Society of Clinical Oncology. All rights reserved. 
Cancer. Stanford, CA, Psychosocial Treatment Lab-
oratory, Department of Psychiatry and Behavioral
Sciences, Stanford University School of Medicine,.
1991
27. Li M, Macedo A, Crawford S, et al: Easier said
than done: Keys to successful implementation of the
Distress Assessment and Response Tool (DART)
program. J Oncol Pract 12:e513-e526, 2016
28. Zimmermann C, Seccareccia D, Clarke A, et al:
Bringing palliative care to a Canadian cancer center:
The palliative care program at Princess Margaret
Hospital. Support Care Cancer 14:982-987, 2006
29. Hannon B, Swami N, Pope A, et al: The on-
cology palliative care clinic at the Princess Margaret
Cancer Centre: An early intervention model for pa-
tients with advanced cancer. Support Care Cancer
23:1073-1080, 2015
30. Ellis J, Lin J, Walsh A, et al: Predictors of re-
ferral for specialized psychosocial oncology care in
patients with metastatic cancer: The contributions of
age, distress, and marital status. J Clin Oncol 27:
699-705, 2009
31. American Psychiatric Association: Diagnostic
and Statistical Manual of Mental Disorders, Fourth
Edition, Text Revision (DSM-IV-TR). Washington, DC,
American Psychiatric Publishing, 2000
32. Ell K, Xie B, Quon B, et al: Randomized con-
trolled trial of collaborative care management of
depression among low-income patients with cancer.
J Clin Oncol 26:4488-4496, 2008
33. First MB, Spitzer RL, Gibbon M, et al: Struc-
tured Clinical Interview for DSM-IV-TR Axis I Disor-
ders, Research Version, Non-Patient Edition. (SCID-I/
NP). New York, NY, Biometrics Research, New York
State Psychiatric Institute, 2010
34. Spitzer RL, Kroenke K, Williams JBW, et al: A
brief measure for assessing generalized anxiety
disorder: The GAD-7. Arch Intern Med 166:
1092-1097, 2006
35. Lo C, Hales S, Zimmermann C, et al: Mea-
suring death-related anxiety in advanced cancer:
Preliminary psychometrics of the Death and Dying
Distress Scale. J Pediatr Hematol Oncol 33:
S140-S145, 2011 (suppl 2)
36. Krause S, Rydall A, Hales S, et al: Initial vali-
dation of the Death and Dying Distress Scale for
the assessment of death anxiety in patients with
advanced cancer. J Pain Symptom Manage 49:
126-134, 2015
37. Peterman AH, Fitchett G, Brady MJ, et al:
Measuring spiritual well-being in people with cancer:
The functional assessment of chronic illness therapy–
Spiritual Well-Being Scale (FACIT-Sp). Ann BehavMed
24:49-58, 2002
38. Canada AL, Murphy PE, Fitchett G, et al: A
3-factor model for the FACIT-Sp. Psychooncology 17:
908-916, 2008
39. Breitbart W, Rosenfeld B, Gibson C, et al:
Meaning-centered group psychotherapy for patients
with advanced cancer: A pilot randomized controlled
trial. Psychooncology 19:21-28, 2010
40. Lo C, Burman D, Swami N, et al: Validation of
the QUAL-EC for assessing quality of life in patients
with advanced cancer. Eur J Cancer 47:554-560,
2011
41. Steinhauser KE, Bosworth HB, Clipp EC, et al:
Initial assessment of a new instrument to measure
quality of life at the end of life. J Palliat Med 5:
829-841, 2002
42. Lo C, Walsh A, Mikulincer M, et al: Measuring
attachment security in patients with advanced can-
cer: Psychometric properties of a modified and brief
Experiences in Close Relationships scale. Psy-
chooncology 18:490-499, 2009
43. Brennan KA, Clark CL, Shaver PR: Self-report
measurement of adult attachment: An integrative
overview, in Simpson JA, Rholes WS (eds), Attach-
ment Theory and Close Relationships. New York, NY,
Guilford, 1998:pp. 46-76.
44. Philipp R, Vehling S, Scheffold K, et al: At-
tachment insecurity in advanced cancer patients:
Psychometric properties of the German version of the
Brief Experiences in Close Relationships Scale (ECR-
M16-G). J Pain Symptom Manage 54:555-562, 2017
45. Olson DH, Larson PJ: PREPARE/ENRICH:
Customized Version. Minneapolis, MN, Life In-
novations, 2009
46. Tedeschi RG, Calhoun LG: The Posttraumatic
Growth Inventory: Measuring the positive legacy of
trauma. J Trauma Stress 9:455-471, 1996
47. Stanton AL, Bower JE, Low CA: Posttraumatic
growth after cancer, in Calhoun LG, Tedeschi RG
(eds), Handbook of Posttraumatic Growth. New York,
NY, Psychology Press, 2014, pp 138-175
48. Kissane DW, Wein S, Love A, et al: The De-
moralization Scale: A report of its development and
preliminary validation. J Palliat Care 20:269-276, 2004
49. Karnofsky D, Burchenal JH: The clinical eval-
uation of chemotherapeutic agents in cancer, in
MacLeod CM (ed), Evaluation of Chemotherapeutic
Agents. New York, NY, Columbia University Press,
1949, pp 191-205
50. Portenoy RK, Thaler HT, Kornblith AB, et al: The
Memorial Symptom Assessment Scale: An instrument
for the evaluation of symptom prevalence, characteristics
and distress. Eur J Cancer 30A:1326-1336, 1994
51. Cohen J. Statistical Power Analyses for the
Behavioral Sciences (ed 2). Hillsdale, NJ, Lawrence
Erlbaum, 1988




53. Benjamini Y, Hochberg Y: Controlling the false
discovery rate: A practical and powerful approach to
multiple testing. J R Stat Soc B 57:289-300, 1995
54. Thekkumpurath P, Walker J, Butcher I, et al:
Screening formajor depression in cancer outpatients:
The diagnostic accuracy of the 9-item patient health
questionnaire. Cancer 117:218-227, 2011
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Appendix




This evaluation is completed on the basis of the case discussion in group supervision and the therapist’s skills as demonstrated
in those sessions. Each case presented will have one evaluation form completed. If a skill was not demonstrated in situations that
demanded it, then the skill should be rated negatively. If a skill was not demonstrated because it was not applicable, the item can be
left blank.
1: Needs improvement 2: Satisfactory 3: Excellent
The Therapeutic Relationship
1. ___ Shows empathic understanding of patient experiences
2. ___ Responds genuinely/honestly to patient thoughts and feelings
3. ___ Promotes reflexive awareness (ability to consider multiple psychological responses to an event)
4. ___ Acknowledges the realities of the patient’s condition/situation
5. ___ Maintains professional boundaries while engaging with patient experiences
6. ___ Demonstrates investment/motivation/engagement in the therapeutic process
Modulating Affect
7. ___ Is able to appropriately modulate the emotional state of the patient
8. ___ Demonstrates comfort with emotional distress
9. ___ Helps increase patient ability to think about/manage negative emotions/events
Shifting Frame
10.___ Shifts among supportive, exploratory, and problem-solving therapeutic frames as necessary
11.___ Adjusts the content and timing of sessions on the basis of the patient’s physical and psychological state
Interpretations
12.___ Offers potential explanations for the patient’s pattern of distress, thoughts, or behaviors
13.___ Offers interpretations in the spirit of dialogue and exchange between therapist and patient
Rate the therapist’s skills when addressing each domain, if applicable.
1: Needs improvement 2: Satisfactory 3: Excellent
Symptom Management and Communication With Health Care Providers
14.___ Encourages better understanding of disease
15.___ Encourages patient’s active involvement in medical care
16.___ Promotes patient consideration of treatment options
17.___ Supports communication with health care providers
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Changes in Self and Relations With Close Others
18.___ Explores patient feelings about his/her life history
19.___ Validates patient’s sense of worth in light of his/her accomplishments
20.___ Acknowledges disappointments or regrets that the patient has experienced
21.___ Explores the relational changes imposed by disease
22.___ Explores fears and anxieties about dependency and loss of autonomy
23.___ Encourages appropriate communication and support giving/taking from close others
Spirituality or Sense of Meaning and Purpose
24.___ Explores the patient’s spiritual beliefs and/or sense of meaning and purpose in life
25.___ Supports understanding of the personal meaning of their experience of suffering and dying
26.___ Evaluates priorities and goals in the face of advanced disease
27.___ Helps to create new meanings regarding the patient’s life trajectory, goals, and suffering
Thinking of the Future, Hope, and Mortality
28.___ Explores patient attitudes towards the future (ie, hopes and fears about living and dying)
29.___ Allows expression of sadness and anxiety about the progression of disease
30.___ Explores feelings about death and dying
31.___ Promotes discussion of advance care planning















Domain 1 Domain 2 Domain 3 Domain 4
Therapeutic Content
Fig A1. Treatment integrity ratings (n = 51). Values on the y-axis indicate the following ratings: 1 = needs improvement, 2 = satisfactory, 3 = excellent. The therapeutic
relationship refers to the therapist’s ability to support patient reflectionwithin an empathic relationship. Modulating affect refers to being able to assist patients inmanaging
negative emotions. Shifting frame refers to being able to adjust one’s clinical approach on the basis of patient needs. Interpretations refer to the ability to offer psychological
explanations to foster dialogue with the patient. Domain 1, symptommanagement and communication with health care providers; domain 2, changes in self and relations
with close others; domain 3, spirituality or sense of meaning and purpose; domain 4, thinking of the future, hope, and mortality. See the Treatment Integrity Scale:
Managing Cancer And Living Meaningfully Evaluation of Therapist Competencies.
jco.org © 2018 by American Society of Clinical Oncology
Psychological Intervention for Patients With Advanced Cancer
Downloaded from ascopubs.org by James Cook University on August 30, 2021 from 137.219.201.141
Copyright © 2021 American Society of Clinical Oncology. All rights reserved. 





No. of participants 154 151
PHQ-9: depressive symptoms
t0 0 (0) 0 (0)
t1 17 (26) 21 (32)
t2 23 (36) 29 (44)
SCID: major depression
t0 0 (0) 1 (2)
t1 19 (29) 23 (34)
t2 26 (40) 30 (45)
GAD-7: generalized anxiety
t0 1 (1) 0 (0)
t1 21 (33) 25 (38)
t2 27 (41) 32 (48)
DADDS: death anxiety (total sample)
t0 0 (0) 0 (0)
t1 20 (31) 25 (37)
t2 25 (39) 32 (49)
FACIT-Sp-12: spiritual well-being
t0 0 (0) 0 (0)
t1 21 (33) 25 (38)
t2 25 (38) 32 (48)
QUAL-EC: preparation for end of life
t0 0 (0) 0 (0)
t1 21 (33) 25 (38)
t2 25 (39) 32 (48)
QUAL-EC: relationship with health care provider
t0 0 (0) 0 (0)
t1 21 (33) 25 (38)
t2 25 (39) 32 (49)
QUAL-EC: life completion
t0 0 (0) 0 (0)
t1 21 (33) 25 (38)
t2 25 (39) 32 (48)
ECR-M16: attachment insecurity
t0 0 (0) 0 (0)
t1 21 (33) 25 (38)
t2 25 (38) 33 (50)
CCS: couple communication
t0 25 (39) 21 (31)
t1 41 (63) 39 (59)
t2 47 (73) 44 (67)
PTGI: post-traumatic growth
t0 0 (0) 0 (0)
t1 22 (34) 26 (39)
t2 25 (39) 32 (48)
DS: demoralization
t0 0 (0) 0 (0)
t1 23 (35) 25 (38)
t2 25 (38) 32 (48)
NOTE. CALM = UC + CALM.
Abbreviations: CALM, Managing Cancer And Living Meaningfully; CCS, Couple
Communication Scale; DADDS, Death and Dying Distress Scale; DS, De-
moralization Scale; ECR-M16, modified Experiences in Close Relationships
Scale; FACIT-Sp-12, Functional Assessment of Chronic Illness Therapy-Spiritual
Well-Being Scale; GAD-7, Generalized Anxiety Disorder-7; PHQ-9, Patient Health
Questionnaire-9; PTGI, Posttraumatic Growth Inventory; QUAL-EC, Quality of
Life at the End of Life Cancer Scale; SCID, Structured Clinical Interview for DSM-
IV-TR Disorders; t0, baseline assessment; t1, 3-month assessment (primary end
point); t2, 6-month assessment (trial end point); UC, usual care.
© 2018 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
Rodin et al
Downloaded from ascopubs.org by James Cook University on August 30, 2021 from 137.219.201.141
Copyright © 2021 American Society of Clinical Oncology. All rights reserved. 
Table A2. Subanalyses of Participants With High and Low Death Anxiety at Baseline by Trial Arm
Secondary Outcome by Time UC CALM D 95% CI d P
DADDS in high death anxiety group ($ 47 points)
t0
Mean (SD) 55.02 (7.19) 56.09 (8.06) — — — —
No. of participants 49 35
t1
Mean (SD) 41.03 (18.71) 42.19 (17.95) 20.87 29.01 to 7.27 0.05 .83
No. of participants 39 27
t2
Mean (SD) 40.73 (14.05) 42.71 (19.43) 21.68 29.23 to 5.87 0.10 .66
No. of participants 37 28
DADDS in low death anxiety group (, 25 points)
t0
Mean (SD) 13.70 (7.47) 14.56 (6.65) — — — —
No. of participants 37 48
t1
Mean (SD) 15.07 (14.00) 17.65 (13.61) 21.54 27.55 to 4.47 0.11 .61
No. of participants 29 40
t2
Mean (SD) 15.21 (15.57) 20.48 (12.79) 24.34 210.60 to 1.93 0.31 .17
No. of participants 29 33
NOTE.We hypothesized that the effects of intervention would vary dependent on the levels of death anxiety (low, moderate, or high) that patients were experiencing.56
We expected that the moderate group would exhibit the most benefit because participants would have sufficient awareness of the threat of mortality and resiliency to
address this issue and prepare for end of life. Those in the high and low groups were expected to show less or no benefit. Those in the high group were expected to have
more intractable physical and psychosocial concerns that caused their scores to be elevated into this range, and that their death anxietymay be less amenable to change.
Those in the low group might be subject to floor effects or may lack sufficient awareness of the threat of mortality to be able to show benefit on distress outcomes over
time. D is the regression-estimated mean difference between groups controlled for baseline. Cohen’s d (effect size) is the standardized mean difference. Effect sizes of
0.20 to 0.50 are considered small to medium.51
Abbreviations: CALM, Managing Cancer And Living Meaningfully; DADDS, Death and Dying Distress Scale; SD, standard deviation; t0, baseline assessment; t1,
3-month assessment (primary end point); t2, 6-month assessment (trial end point); UC, usual care.
Table A3. Results From Mixed Models for the Trial Arm 3 Time Interactions
Outcome




PHQ-9: depressive symptoms .048* 0.499
GAD-7: generalized anxiety .590 0.526
DADDS: death anxiety .850 0.656
FACIT-Sp-12: spiritual well-being .162 0.750
QUAL-EC: preparation for end of life .011* 0.715
QUAL-EC: relationship with health
care provider
.110 0.651
QUAL-EC: life completion .312 0.630
ECR-M16: attachment insecurity .422 0.654
CCS: couple communication .004* 0.731
PTGI: post-traumatic growth .439 0.703
DS: demoralization .201 0.715
NOTE. Mixed models were conducted by regressing each outcome on the trial
arm (UC, CALM), time (t0, t1, and t2), and their interaction, with intercepts set as
random effects. Listed are results for the primary and secondary outcomes and
their trial arm 3 time interactions. The CALM group was expected to show less
distress and greater benefit over time relative to UC. There were significant
effects on the PHQ-9 (reflecting a steeper decline in severity of depressive
symptoms in CALM v UC), preparation for end of life (reflecting greater prep-
aration for end of life in CALM v UC), and CCS (reflecting an increase in couple
communication in UC v CALM at baseline, although the two groups come to
parity over time).
Abbreviations: CALM, Managing Cancer And Living Meaningfully; CCS, Couple
Communication Scale; DADDS, Death and Dying Distress Scale; DS, De-
moralization Scale; ECR-M16, modified Experiences in Close Relationships
Scale; FACIT-Sp-12, Functional Assessment of Chronic Illness Therapy-Spiritual
Well-Being Scale; GAD-7, Generalized Anxiety Disorder-7; PHQ-9, Patient Health
Questionnaire-9; PTGI, Posttraumatic Growth Inventory; QUAL-EC, Quality of
Life at the End of Life Cancer Scale; UC, usual care.
*P , .05.
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Table A4. Significant Trial Arm 3 Time Regression-Estimated Means
Outcome
UC CALM
̅x 95% CI ̅x 95% CI
PHQ-9
t0 7.41 6.67 to 8.16 7.45 6.70 to 8.20
t1 6.93 6.13 to 7.73 5.88 5.05 to 6.70
t2 6.72 5.90 to 7.54 5.36 4.50 to 6.22
QUAL-EC: preparation for end of life
t0 11.62 11.03 to 12.22 12.07 11.47 to 12.67
t1 11.80 11.17 to 12.43 13.10 12.46 to 13.75
t2 12.12 11.49 to 12.76 13.61 12.95 to 14.27
CCS: couple communication
t0 36.47 35.08 to 37.86 39.07 37.71 to 40.44
t1 38.28 36.81 to 39.75 38.34 36.89 to 39.80
t2 38.00 36.48 to 39.51 38.47 36.98 to 39.96
NOTE. Listed are the mixed-model estimated means that explain the significant trial arm3 time interactions. CALM showed a pattern of steeper decline in depressive
symptoms over time and greater end-of-life preparation over time compared with UC. With regard to the CCS, the two groups seemed to differ at baseline and came to
parity over time. CALM = UC + CALM.
Abbreviations: CALM, Managing Cancer And Living Meaningfully; CCS, Couple Communication Scale (higher scores reflect greater communication); PHQ-9, Patient
Health Questionnaire-9 (higher scores reflect greater depressive symptom severity); QUAL-EC, Quality of Life at the End of Life Cancer Scale (higher scores reflect better
preparation for end of life); t0, baseline assessment; t1, 3-month assessment (primary end point); t2, 6-month assessment (trial end point); UC, usual care.
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